Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Scott

Showing results (21-30 of 139) with videos related to

Pageof 14
Sort By:
Drug Safety|July 18, 2020
Thromboembolism and Janus Kinase InhibitorsFowzia Ibrahim, David L Scott
The Journal of Rheumatology|February 5, 2004
Translating research into practice: acetaminophen in osteoarthritis revisitedDavid L Scott, Gabrielle Kingsley
Annals of the Rheumatic Diseases|May 14, 2009
New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?David L Scott, Andrew Cope
Nature Clinical Practice. Rheumatology|December 3, 2008
NICE guidelines on anti-tumor necrosis factor therapy for RADavid L Scott, Sophia Steer
Nature Reviews. Rheumatology|November 2, 2010
Clinical trials: Tight control in early RA pays off in the long runDavid L Scott, Anna Kowalczyk
Open Access Rheumatology : Research and Reviews|August 25, 2011
Certolizumab in the long-term treatment of rheumatoid arthritisAbdul Khan, David L Scott
Psoriasis (Auckland, N.Z.)|February 2, 2018
Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic reviewGabrielle H Kingsley, David L Scott
Best Practice & Research. Clinical Rheumatology|December 6, 2011
Co-morbidities in established rheumatoid arthritisNicola J Gullick, David L Scott
Drugs|March 11, 2014
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?Ian C Scott, David L Scott
Rheumatology (Oxford, England)|February 9, 2013
Comment on: A randomized placebo-controlled trial of methotrexate in psoriatic arthritis: replyGabrielle H Kingsley, David L Scott
Pageof 14

Showing results (21-30 of 139) with videos related to

Sort By:
Pageof 14
Drug Safety|July 18, 2020
Thromboembolism and Janus Kinase InhibitorsFowzia Ibrahim, David L Scott
The Journal of Rheumatology|February 5, 2004
Translating research into practice: acetaminophen in osteoarthritis revisitedDavid L Scott, Gabrielle Kingsley
Annals of the Rheumatic Diseases|May 14, 2009
New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?David L Scott, Andrew Cope
Nature Clinical Practice. Rheumatology|December 3, 2008
NICE guidelines on anti-tumor necrosis factor therapy for RADavid L Scott, Sophia Steer
Nature Reviews. Rheumatology|November 2, 2010
Clinical trials: Tight control in early RA pays off in the long runDavid L Scott, Anna Kowalczyk
Open Access Rheumatology : Research and Reviews|August 25, 2011
Certolizumab in the long-term treatment of rheumatoid arthritisAbdul Khan, David L Scott
Psoriasis (Auckland, N.Z.)|February 2, 2018
Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic reviewGabrielle H Kingsley, David L Scott
Best Practice & Research. Clinical Rheumatology|December 6, 2011
Co-morbidities in established rheumatoid arthritisNicola J Gullick, David L Scott
Drugs|March 11, 2014
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?Ian C Scott, David L Scott
Rheumatology (Oxford, England)|February 9, 2013
Comment on: A randomized placebo-controlled trial of methotrexate in psoriatic arthritis: replyGabrielle H Kingsley, David L Scott
Pageof 14